Here's why the Alterity Therapeutics (ASX:ATH) share price blasted 20% higher today

The Alterity Therapeutics share price is having a monster day, posting a gain of more than 20%. Let's take a look at what's been happening.

The Alterity Therapeutics Ltd (ASX: ATH) share price is soaring today, up by more than 20% at the time of writing. The Alterity share price is currently trading at 4.7 cents a share.

Alterity Therapeutics is an Australian biotechnology company that focuses on commercialising research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders.

A medical researcher works on a bichip, indicating share price movement in ASX tech companies

Image Source: Getty Images

Michael J Fox Foundation puts up funding, Alterity share price soars

Alterity Therapeutics announced today that the company has been awarded a US$495,000 research grant from The Michael J. Fox Foundation for Parkinson's Research.

The funding will be put toward determining the optimal dosing of ATH434 for Parkinson's disease (PD) based on imaging of brain iron.

After Alzheimer's disease, PD is the second most common age-related neurodegenerative disorder. It occurs when brain cells that make dopamine degenerate and ultimately die. 

ATH434 is Alterity Therapeutics' lead drug candidate for the treatment of PD. It's considered the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.

This is the second grant the company has received from The Michael J. Fox Foundation to continue its ATH434 research.

Highlights from the Alterity Therapeutics Q2 FY21 report

In addition to today's news, Alterity Therapeutics released its second-quarter FY21 report on 28 January 2021.

Following a successful $35 million placement, Alterity advised that the company will continue to progress the Phase 2 clinical development program for ATH434. 

Some of the big institutional Alterity Therapeutics shareholders include UBS AG, Australia, Merrill Lynch International Limited, and Credit Suisse AG.

Discussing Q2 FY21 achievements, the company's new CEO Dr David Stamler said: 

We've made important progress throughout the quarter with our commercialisation program for ATH434, including the initiation of our MSA natural history study and growing scientific validation of our library of compounds. I look forward to evaluating new opportunities for PBT2 in the important area of antibiotic resistance. We are well capitalized to continue to advance the company in the coming year.

Geoffrey Kempler, who founded the company in November 1997, stepped down from the CEO role and continues as non-executive chair.

The Alterity share price has powered up roughly 116% over the previous 12-month period.

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Read more »